Pub Date : 2025-11-01DOI: 10.1016/j.lanhl.2025.100795
Carolyn E Schwartz
{"title":"A pragmatic application with clear personal impact","authors":"Carolyn E Schwartz","doi":"10.1016/j.lanhl.2025.100795","DOIUrl":"10.1016/j.lanhl.2025.100795","url":null,"abstract":"","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 11","pages":"Article 100795"},"PeriodicalIF":14.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145640782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.lanhl.2025.100796
Changyuan Yang MD , Hanneke Joosten MD PhD , Lynne Chepulis PhD , Fabiana Rossi Varallo PhD , Peter van Dijk MD PhD , Deidra C Crews MD , Priya Vart PhD
Chronic kidney disease (CKD) is common among older adults, with more than a third of individuals older than 65 years having moderate to severe CKD globally. Management of CKD in older adults is often complex because of multiple comorbidities, polypharmacy, and frailty. However, older adults remain under-represented in clinical trials for both type 2 diabetes (T2D), which is the leading risk factor for CKD, and CKD itself. Recent analyses show consistent low representation of older adults in T2D trials. Similarly, participants of dialysis trials tend to be younger, healthier, and have a lower mortality rate than individuals in the real-world dialysis population, and even greater age disparities are reported in trials for non-dialysis-dependent CKD. This under-representation limits the evidence base for treating older adults and often compels clinicians to extrapolate findings from younger populations or rely on observational data. Consequently, both undertreatment and overtreatment of T2D and CKD might occur. Excluding older adults from trial participation leads to society bearing the costs of avoidable harms from preventable adverse events, inappropriate medication use, and missed opportunities to improve functional outcomes in an ageing population. Addressing this age gap in trial population and target treatment population is crucial to ensure evidence-based, equitable care for older adults. In this Personal View, we explore the barriers of under-representation of older adults and propose strategies to enhance their inclusion in future trials for T2D and CKD.
{"title":"Bridging the age gap: improving representation of older adults in clinical trials for type 2 diabetes and chronic kidney disease","authors":"Changyuan Yang MD , Hanneke Joosten MD PhD , Lynne Chepulis PhD , Fabiana Rossi Varallo PhD , Peter van Dijk MD PhD , Deidra C Crews MD , Priya Vart PhD","doi":"10.1016/j.lanhl.2025.100796","DOIUrl":"10.1016/j.lanhl.2025.100796","url":null,"abstract":"<div><div>Chronic kidney disease (CKD) is common among older adults, with more than a third of individuals older than 65 years having moderate to severe CKD globally. Management of CKD in older adults is often complex because of multiple comorbidities, polypharmacy, and frailty. However, older adults remain under-represented in clinical trials for both type 2 diabetes (T2D), which is the leading risk factor for CKD, and CKD itself. Recent analyses show consistent low representation of older adults in T2D trials. Similarly, participants of dialysis trials tend to be younger, healthier, and have a lower mortality rate than individuals in the real-world dialysis population, and even greater age disparities are reported in trials for non-dialysis-dependent CKD. This under-representation limits the evidence base for treating older adults and often compels clinicians to extrapolate findings from younger populations or rely on observational data. Consequently, both undertreatment and overtreatment of T2D and CKD might occur. Excluding older adults from trial participation leads to society bearing the costs of avoidable harms from preventable adverse events, inappropriate medication use, and missed opportunities to improve functional outcomes in an ageing population. Addressing this age gap in trial population and target treatment population is crucial to ensure evidence-based, equitable care for older adults. In this Personal View, we explore the barriers of under-representation of older adults and propose strategies to enhance their inclusion in future trials for T2D and CKD.</div></div>","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 11","pages":"Article 100796"},"PeriodicalIF":14.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145606714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.lanhl.2025.100790
Amaia Calderón-Larrañaga PhD , Elisa Fabbri MD , Ana Isabel González MD , Prof Rafael Perera-Salazar PhD , Nina Grede PhD , Prof Bruce Guthrie MD , Prof José M Valderas MD , Caterina Gregorio PhD , Prof Christiane Muth MD , Davide L Vetrano MD , Prof Gabriele Meyer PhD , Luigi Ferrucci MD , Jeanet W Blom MD , Kerstin Bernartz MSc , Lara Schürmann MSc , Maria Hanf MSc , Prof Martin Scherer MD , Prof Michael A Steinman MD , Prof Mieke Rijken PhD , Prof Sharon Straus MD , Marjan van den Akker PhD
Multimorbidity, the coexistence of multiple chronic diseases or conditions, poses a major challenge for health-care systems worldwide. Traditional research has largely relied on cross-sectional studies, offering limited insight into multimorbidity evolution over time. This Personal View advocates for a paradigm shift towards longitudinal approaches that capture multimorbidity trajectories. Tracking the sequence, pace, and severity of disease accumulation can enhance our understanding of underlying mechanisms, inform early interventions, and improve patient care. Drawing on expert discussions from an international workshop held in Bielefeld, Germany, in May, 2024, we outline key themes and findings to guide future research on the dynamic processes underlying multimorbidity trajectories. Specifically, we summarise previous work, examine the challenges and opportunities of existing data resources, and highlight priority areas for further investigation. Advancing this field will require the standardisation of longitudinal multimorbidity phenotypes, integration of health and social care processes, and testing the usefulness of trajectories for patient-relevant outcomes and risk stratification. Progress will also depend on methodological innovation, patient and public involvement, harmonisation of diverse data sources, and close interdisciplinary collaboration. Ultimately, a trajectory-based framework for multimorbidity research can enable more personalised, efficient, and equitable health-care strategies, improving outcomes in ageing populations.
{"title":"Understanding changes in complex care needs over time: key research insights into multimorbidity trajectories","authors":"Amaia Calderón-Larrañaga PhD , Elisa Fabbri MD , Ana Isabel González MD , Prof Rafael Perera-Salazar PhD , Nina Grede PhD , Prof Bruce Guthrie MD , Prof José M Valderas MD , Caterina Gregorio PhD , Prof Christiane Muth MD , Davide L Vetrano MD , Prof Gabriele Meyer PhD , Luigi Ferrucci MD , Jeanet W Blom MD , Kerstin Bernartz MSc , Lara Schürmann MSc , Maria Hanf MSc , Prof Martin Scherer MD , Prof Michael A Steinman MD , Prof Mieke Rijken PhD , Prof Sharon Straus MD , Marjan van den Akker PhD","doi":"10.1016/j.lanhl.2025.100790","DOIUrl":"10.1016/j.lanhl.2025.100790","url":null,"abstract":"<div><div>Multimorbidity, the coexistence of multiple chronic diseases or conditions, poses a major challenge for health-care systems worldwide. Traditional research has largely relied on cross-sectional studies, offering limited insight into multimorbidity evolution over time. This Personal View advocates for a paradigm shift towards longitudinal approaches that capture multimorbidity trajectories. Tracking the sequence, pace, and severity of disease accumulation can enhance our understanding of underlying mechanisms, inform early interventions, and improve patient care. Drawing on expert discussions from an international workshop held in Bielefeld, Germany, in May, 2024, we outline key themes and findings to guide future research on the dynamic processes underlying multimorbidity trajectories. Specifically, we summarise previous work, examine the challenges and opportunities of existing data resources, and highlight priority areas for further investigation. Advancing this field will require the standardisation of longitudinal multimorbidity phenotypes, integration of health and social care processes, and testing the usefulness of trajectories for patient-relevant outcomes and risk stratification. Progress will also depend on methodological innovation, patient and public involvement, harmonisation of diverse data sources, and close interdisciplinary collaboration. Ultimately, a trajectory-based framework for multimorbidity research can enable more personalised, efficient, and equitable health-care strategies, improving outcomes in ageing populations.</div></div>","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 11","pages":"Article 100790"},"PeriodicalIF":14.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145640755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The WHO Integrated Care for Older People programme: a key strategy for addressing ageing in sub-Saharan Africa","authors":"Maturin Tabue-Teguo , Marie-Josiane Ntsama-Essomba , Moustapha Drame , Mamadou Coume , Nadine Simo","doi":"10.1016/j.lanhl.2025.100784","DOIUrl":"10.1016/j.lanhl.2025.100784","url":null,"abstract":"","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 10","pages":"Article 100784"},"PeriodicalIF":14.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145472203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1016/j.lanhl.2025.100770
Prof Nicholas F Taylor PhD , Paul D O’Halloran PhD , Prof Jennifer J Watts MCom(Econ) , Casey L Peiris PhD , Prof Luke A Prendergast PhD , Prof Judi Porter PhD , Prof Katherine E Harding PhD , David A Snowdon PhD , Christina L Ekegren PhD , Made U Rimayanti PhD , Raphael Hau FRACS , Shalika Bohingamu Mudiyanselage MHHSM , Kate E Noeske BPhysio , Megan Snowdon BPhysio , Scott Williams BAHons , Prof Nora Shields PhD
<div><h3>Background</h3><div>Hip fracture has profound psychosocial effects but there is little guidance about how to incorporate management of psychosocial factors into rehabilitation. We aimed to assess the effect of telephone-based motivational interviewing on physical activity in community-dwelling older adults after hip fracture.</div></div><div><h3>Methods</h3><div>We conducted a 12-month, assessor-masked, open-label, multisite, randomised controlled trial in three health networks (Eastern Health, Peninsula Health, and Alfred Health) in Melbourne, VIC, Australia. Each health network included acute hospitals, sub-acute (rehabilitation) hospitals, and community rehabilitation programmes from which eligible participants were recruited. Community-dwelling adults with hip fracture, aged 65 years and older, were randomly assigned (1:1) by an external provider with a random number generator to an experimental group receiving ten 30-min sessions of motivational interviewing over 16 weeks from one of 13 trained health professionals or to an attention-control group receiving an equivalent dosage of dietary advice from one of nine accredited dietitians. Assessors were masked to group allocation. The primary outcome, assessed in the intention-to-treat population, was physical activity expressed as accelerometer-measured daily walking time at week 52. All available data were used in the linear mixed effects models. To account for missing data, multiple imputation was completed as a sensitivity analysis. The study was registered prospectively (ACTRN12619000936123).</div></div><div><h3>Findings</h3><div>From Sept 29, 2019, to June 27, 2022, 1246 potentially eligible patients were screened, 1046 were excluded (611 were deemed ineligible, 359 declined to participate, and 76 were unable to be contacted) and the resulting 200 were randomly assigned to an intervention (98 assigned to the motivational interviewing group and 102 assigned to the nutritional education control group). 146 (73%) participants were female, 54 (27%) were male, the average age of participants was 79 years (SD 7), and participants were a mean of 89 days (SD 40) days post-surgery at baseline. Daily walking time at week 52 was a median of 53·1 min (IQR 28·8 to 73·8) in the motivational interviewing group and 63·7 min (42·6 to 89·2) in the control group, with no significant between-group differences (mean difference 4·1% [95% CI –16·6 to 21·1). There were no serious harms related to the intervention. There were seven deaths during the period from baseline to week 52, three in the motivational interviewing group and four in the control group. There were a small number of non-serious adverse events related to the intervention with a total of seven (1%) short-term skin reactions out of 668 assessments in response to the activity monitor being held in place on the thigh with dressing.</div></div><div><h3>Interpretation</h3><div>Motivational interviewing was no more effective than dietary advice
{"title":"The effect of motivational interviewing on physical activity after hip fracture: a multisite, open-label, randomised controlled trial in Australia","authors":"Prof Nicholas F Taylor PhD , Paul D O’Halloran PhD , Prof Jennifer J Watts MCom(Econ) , Casey L Peiris PhD , Prof Luke A Prendergast PhD , Prof Judi Porter PhD , Prof Katherine E Harding PhD , David A Snowdon PhD , Christina L Ekegren PhD , Made U Rimayanti PhD , Raphael Hau FRACS , Shalika Bohingamu Mudiyanselage MHHSM , Kate E Noeske BPhysio , Megan Snowdon BPhysio , Scott Williams BAHons , Prof Nora Shields PhD","doi":"10.1016/j.lanhl.2025.100770","DOIUrl":"10.1016/j.lanhl.2025.100770","url":null,"abstract":"<div><h3>Background</h3><div>Hip fracture has profound psychosocial effects but there is little guidance about how to incorporate management of psychosocial factors into rehabilitation. We aimed to assess the effect of telephone-based motivational interviewing on physical activity in community-dwelling older adults after hip fracture.</div></div><div><h3>Methods</h3><div>We conducted a 12-month, assessor-masked, open-label, multisite, randomised controlled trial in three health networks (Eastern Health, Peninsula Health, and Alfred Health) in Melbourne, VIC, Australia. Each health network included acute hospitals, sub-acute (rehabilitation) hospitals, and community rehabilitation programmes from which eligible participants were recruited. Community-dwelling adults with hip fracture, aged 65 years and older, were randomly assigned (1:1) by an external provider with a random number generator to an experimental group receiving ten 30-min sessions of motivational interviewing over 16 weeks from one of 13 trained health professionals or to an attention-control group receiving an equivalent dosage of dietary advice from one of nine accredited dietitians. Assessors were masked to group allocation. The primary outcome, assessed in the intention-to-treat population, was physical activity expressed as accelerometer-measured daily walking time at week 52. All available data were used in the linear mixed effects models. To account for missing data, multiple imputation was completed as a sensitivity analysis. The study was registered prospectively (ACTRN12619000936123).</div></div><div><h3>Findings</h3><div>From Sept 29, 2019, to June 27, 2022, 1246 potentially eligible patients were screened, 1046 were excluded (611 were deemed ineligible, 359 declined to participate, and 76 were unable to be contacted) and the resulting 200 were randomly assigned to an intervention (98 assigned to the motivational interviewing group and 102 assigned to the nutritional education control group). 146 (73%) participants were female, 54 (27%) were male, the average age of participants was 79 years (SD 7), and participants were a mean of 89 days (SD 40) days post-surgery at baseline. Daily walking time at week 52 was a median of 53·1 min (IQR 28·8 to 73·8) in the motivational interviewing group and 63·7 min (42·6 to 89·2) in the control group, with no significant between-group differences (mean difference 4·1% [95% CI –16·6 to 21·1). There were no serious harms related to the intervention. There were seven deaths during the period from baseline to week 52, three in the motivational interviewing group and four in the control group. There were a small number of non-serious adverse events related to the intervention with a total of seven (1%) short-term skin reactions out of 668 assessments in response to the activity monitor being held in place on the thigh with dressing.</div></div><div><h3>Interpretation</h3><div>Motivational interviewing was no more effective than dietary advice","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 10","pages":"Article 100770"},"PeriodicalIF":14.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145460064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1016/j.lanhl.2025.100774
Prof Rupert A Payne PhD , Prof Peter S Blair PhD , Barbara Caddick PhD , Prof Carolyn A Chew-Graham MD , Prof Tobias Dreischulte PhD , Lorna J Duncan PhD , Prof Bruce Guthrie PhD , Cindy Mann PhD , Roxanne M Parslow PhD , Prof Jeff Round PhD , Prof Chris Salisbury MD , Prof Katrina M Turner PhD , Nicholas L Turner PhD , Deborah McCahon PhD
<div><h3>Background</h3><div>Polypharmacy is a major and growing challenge for patient safety and health outcomes, and associated with inefficient use of resources. Management requires balancing therapeutic benefits and risks, aligned with clinical and patient priorities. High-quality evidence supporting current guidance for the management of polypharmacy is scarce. The aim of the Improving Medicines use in People with Polypharmacy in Primary Care (IMPPP) study was to examine whether a complex intervention could reduce potentially inappropriate prescribing among patients experiencing polypharmacy in primary care.</div></div><div><h3>Methods</h3><div>A pragmatic, open-label, two-arm, parallel cluster-randomised trial was conducted in UK general practices providing National Health Service primary medical care. Practices were required to use the EMIS electronic health records system and have more than 4000 registered patients. For inclusion in the study, participants were required to be aged 18 years or older, prescribed at least five regular medications (ie, medicines recorded in the clinical system as repeat prescriptions, and thus available for recurrent ordering by patients without having to see a clinician) irrespective of when the drug was last issued, and with at least one indicator of potentially inappropriate prescribing identified by an informatics tool. Practices were randomly allocated to deliver the polypharmacy intervention or continue usual care. The complex intervention comprised a structured, collaborative, and patient-centred approach to medication review, supported by informatics, clinician training, performance feedback, and financial incentivisation. In each practice, adults receiving five or more regular medications, with at least one indicator of potentially inappropriate prescribing, were reviewed over a 6-month period. The primary outcome was number of indicators of potentially inappropriate prescribing at 26 weeks’ follow-up, analysed on an intention-to-treat basis. The trial was registered with the ISRCTN registry (90146150) and is complete.</div></div><div><h3>Findings</h3><div>Between Jan 26, 2022, and June 20, 2022, 37 general practices were recruited. 33 745 patients were potentially eligible, and 11 022 of these were randomly sampled for study inclusion. 1471 were excluded after general practitioner screening, 9551 were invited to participate, and 1950 provided consent and were randomly assigned (944 patients from 18 practices assigned to usual care and 1006 patients from 19 practices assigned to the intervention). 1727 participants were enrolled in the trial (836 in the usual care group and 891 in the intervention group). Participants’ median age was 73 years (IQR 66−79), 881 (51%) were male and 846 (49%) were female, and they had a median of four long-term conditions and a median of eight medications. There was no evidence of a difference in the primary outcome of number of potentially inappropriate prescribing indi
背景：多种用药是对患者安全和健康结果的一个重大且日益严峻的挑战，并与资源的低效利用有关。管理需要平衡治疗益处和风险，与临床和患者优先事项保持一致。目前支持多药管理指南的高质量证据很少。改善初级保健中使用多种药物的患者的药物使用（IMPPP）研究的目的是检查复杂干预是否可以减少初级保健中使用多种药物的患者潜在的不适当处方。方法：在英国提供国家卫生服务初级医疗保健的全科实践中进行了一项实用的、开放标签的、双臂的、平行的集群随机试验。诊所被要求使用EMIS电子健康记录系统，并有超过4000名注册患者。为了纳入研究，参与者被要求年满18岁或以上，开具至少五种常规药物（即，临床系统中记录为重复处方的药物，因此患者无需见临床医生即可反复订购），而不考虑药物最后一次开具的时间，并且至少有一个由信息学工具确定的潜在不适当处方指标。实践随机分配，提供综合干预或继续常规护理。复杂的干预包括一个结构化的、协作的、以患者为中心的药物审查方法，由信息学、临床医生培训、绩效反馈和财政激励支持。在每个实践中，接受五种或更多常规药物治疗的成年人，至少有一个潜在的不当处方指标，在6个月的时间内进行审查。主要结果是26周随访时潜在不适当处方的指标数量，以意向治疗为基础进行分析。该试验已在ISRCTN注册中心注册（90146150），并且已经完成。研究结果：在2022年1月26日至2022年6月20日期间，招募了37名全科医生。33 745名患者可能符合条件，其中11 022名患者被随机抽样纳入研究。1471名全科医生筛查后被排除，9551名被邀请参加，1950名提供同意并随机分配（来自18个诊所的944名患者分配到常规护理组，来自19个诊所的1006名患者分配到干预组）。1727名参与者参加了试验（836名在常规护理组，891名在干预组）。参与者的中位年龄为73岁（IQR 66-79），男性881人（51%），女性846人（49%），他们有中位4种长期疾病和中位8种药物。在调整随机化前基线后的26周随访中，干预组和对照组之间潜在不适当的处方指标数量的主要结局没有证据差异（每组平均2.3；平均差异为- 0.007 [95% CI - 0.21至0.20];p= 0.95）。干预组有13人死亡，99人有一次或多次计划外入院，对照组有12人死亡，91人有一次或多次计划外入院。入院或死亡都不被认为与干预有关。解释：复杂的药物优化干预并没有减少多药患者潜在的不适当处方。这些发现与当前推动数字医疗保健解决方案的政策、对临床药学人员的投资以及促进结构化药物审查的政策不一致。应相应地重新审视有效利用这种战略的问题。资助：国家卫生和保健研究所。
{"title":"Optimising polypharmacy management in primary care through general practitioner−pharmacist collaboration, informatics, and enhancing clinician engagement: the IMPPP cluster-randomised trial","authors":"Prof Rupert A Payne PhD , Prof Peter S Blair PhD , Barbara Caddick PhD , Prof Carolyn A Chew-Graham MD , Prof Tobias Dreischulte PhD , Lorna J Duncan PhD , Prof Bruce Guthrie PhD , Cindy Mann PhD , Roxanne M Parslow PhD , Prof Jeff Round PhD , Prof Chris Salisbury MD , Prof Katrina M Turner PhD , Nicholas L Turner PhD , Deborah McCahon PhD","doi":"10.1016/j.lanhl.2025.100774","DOIUrl":"10.1016/j.lanhl.2025.100774","url":null,"abstract":"<div><h3>Background</h3><div>Polypharmacy is a major and growing challenge for patient safety and health outcomes, and associated with inefficient use of resources. Management requires balancing therapeutic benefits and risks, aligned with clinical and patient priorities. High-quality evidence supporting current guidance for the management of polypharmacy is scarce. The aim of the Improving Medicines use in People with Polypharmacy in Primary Care (IMPPP) study was to examine whether a complex intervention could reduce potentially inappropriate prescribing among patients experiencing polypharmacy in primary care.</div></div><div><h3>Methods</h3><div>A pragmatic, open-label, two-arm, parallel cluster-randomised trial was conducted in UK general practices providing National Health Service primary medical care. Practices were required to use the EMIS electronic health records system and have more than 4000 registered patients. For inclusion in the study, participants were required to be aged 18 years or older, prescribed at least five regular medications (ie, medicines recorded in the clinical system as repeat prescriptions, and thus available for recurrent ordering by patients without having to see a clinician) irrespective of when the drug was last issued, and with at least one indicator of potentially inappropriate prescribing identified by an informatics tool. Practices were randomly allocated to deliver the polypharmacy intervention or continue usual care. The complex intervention comprised a structured, collaborative, and patient-centred approach to medication review, supported by informatics, clinician training, performance feedback, and financial incentivisation. In each practice, adults receiving five or more regular medications, with at least one indicator of potentially inappropriate prescribing, were reviewed over a 6-month period. The primary outcome was number of indicators of potentially inappropriate prescribing at 26 weeks’ follow-up, analysed on an intention-to-treat basis. The trial was registered with the ISRCTN registry (90146150) and is complete.</div></div><div><h3>Findings</h3><div>Between Jan 26, 2022, and June 20, 2022, 37 general practices were recruited. 33 745 patients were potentially eligible, and 11 022 of these were randomly sampled for study inclusion. 1471 were excluded after general practitioner screening, 9551 were invited to participate, and 1950 provided consent and were randomly assigned (944 patients from 18 practices assigned to usual care and 1006 patients from 19 practices assigned to the intervention). 1727 participants were enrolled in the trial (836 in the usual care group and 891 in the intervention group). Participants’ median age was 73 years (IQR 66−79), 881 (51%) were male and 846 (49%) were female, and they had a median of four long-term conditions and a median of eight medications. There was no evidence of a difference in the primary outcome of number of potentially inappropriate prescribing indi","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 10","pages":"Article 100774"},"PeriodicalIF":14.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145330076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号